L. Sperling

Influence of chorionicity on perinatal outcome in a large cohort of Danish twin pregnancies.

To assess outcome in twin pregnancies according to chorionicity.

How to identify twins at low risk of spontaneous preterm delivery

The aim of this study was to evaluate transvaginal sonographic assessment of cervical length at 23 weeks as a screening test for spontaneous preterm delivery in order to define a cut‐off value that could be used to select twin pregnancies at low risk of spontaneous preterm delivery.

Increased nuchal translucency, normal karyotype and infant development

To investigate whether chromosomally normal fetuses with a nuchal translucency (NT) ≥ 99th percentile (3.5 mm) in the first trimester have an increased risk of delayed development at 2 years of age.

Cytokines and the risk of preterm delivery in twin pregnancies.

OBJECTIVE: To estimate the association between cytokine levels in twin pregnancies and risk of spontaneous preterm delivery, including the effect of progesterone treatment. METHODS: This secondary analysis of a randomized placebo-controlled trial investigating the effect of progesterone treatment on preterm delivery in twin pregnancies included 523 women with available dried blood spot samples collected before treatment with progesterone (n=258) or placebo (n=265) and after 4–8 weeks of treatment. Samples were analyzed for cytokines using a sandwich immunoassay. Cytokine levels in spontaneous preterm delivery at 34–37 weeks of gestation and spontaneous preterm delivery before 34 weeks of gestation were compared with delivery at 37 weeks of gestation or more for placebo-treated women. The association between interleukin (IL)-8 and risk of spontaneous preterm delivery before 34 weeks of gestation was estimated further, including comparison according to treatment. Statistical analyses included Kruskal-Wallis test, Mann-Whitney U test, linear regression, and Cox regression analysis. RESULTS: We found a statistically significant association between IL-8 and spontaneous preterm delivery. At 23–33 weeks of gestation, the median IL-8 level was 52 pg/mL (interquartile range 39–71, range 19–1,061) for term deliveries compared with 65 pg/mL (interquartile range 43–88, range 14–584) for spontaneous preterm delivery at 34–37 weeks of gestation and 75 pg/mL (interquartile range 57–102, range 22–1,715) for spontaneous preterm delivery before 34 weeks of gestation (P<.001). Risk of spontaneous preterm delivery was associated with a large weekly increase in IL-8 (hazard ratio 2.0, 95% confidence interval [CI] 1.2–3.3). There was no effect of progesterone treatment on IL-8 levels. Levels of IL-8 at 18–24 weeks of gestation were associated with a cervix less than 30 mm (odds ratio 1.8, 95% CI 1.2–2.7). CONCLUSION: Risk of spontaneous preterm delivery before 34 weeks of gestation is increased in women with high IL-8 levels. Progesterone treatment does not affect IL-8 levels. CLINICAL TRIAL REGISTRATION: EudraCT, https://eudract.ema.europa.eu, 2006-000503-41, and ClinicalTrials.gov, www.clinicaltrials.gov, NCT00329914. LEVEL OF EVIDENCE: II

Long‐term effects of prenatal progesterone exposure: neurophysiological development and hospital admissions in twins up to 8 years of age

To perform a neurophysiological follow‐up at 48 or 60 months of age in children exposed prenatally to progesterone compared with a placebo and evaluate their medical histories up to 8 years of age.

OC01.01: Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo-controlled trial on the effect of vaginal micronised progesterone: Oral communication abstracts

L. Rode1,2, K. Klein3, K. Nicolaides4, E. Krampl-Bettelheim3, I. Vogel5, H. Larsen6, A. Holmskov7, K. Riis Andreasen8, N. Uldbjerg9, J. Ramb10, B. Bødker11, L. Skibsted12,2, L. Sperling13, S. Hinterberger14, L. Krebs15, H. Zingenberg16, E. Weiss17, I. Strobl18, L. Laursen19, J. Tranberg Christensen20, B. M. Hansen21, A. Lando21, A. Tabor1,2 1Department of Fetal Medicine 4002, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; 2Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark; 3Department of Obstetrics & Gynecology, Medical University of Vienna, Vienna, Austria; 4Harris Birthright Research Centre for Fetal Medicine, King’s College Hospital, London, United Kingdom; 5Department of Clinical Genetics, Aarhus University Hospital Skejby, Aarhus, Denmark; 6Department of Obstetrics & Gynecology, Aalborg Hospital, Aalborg, Denmark; 7Department of Obstetrics & Gynecology, Viborg Hospital, Viborg, Denmark; 8Department of Obstetrics & Gynecology, Hvidovre Hospital, Hvidovre, Denmark; 9Department of Obstetrics & Gynecology, Aarhus University Hospital Skejby, Aarhus, Denmark; 10Department of Obstetrics & Gynecology, Sønderborg Hospital, Sønderborg, Denmark; 11Department of Obstetrics & Gynecology, Hillerød Hospital, Hillerød, Denmark; 12Department of Obstetrics & Gynecology, Roskilde University Hospital, Roskilde, Denmark; 13Department of Obstetrics & Gynecology, Herlev Hospital, Herlev, Denmark; 14Department of Obstetrics & Gynecology, General Hospital of Klagenfurt, Klagenfurt, Austria; 15Department of Obstetrics & Gynecology, Holbæk Hospital, Holbæk, Denmark; 16Department of Obstetrics & Gynecology, Glostrup Hospital, Glostrup, Denmark; 17Department of Obstetrics & Gynecology, Medical University of Graz, Graz, Austria; 18Department of Obstetrics & Gynecology, Medical University of Innsbruck, Innsbruck, Austria; 19Department of Obstetrics & Gynecology, Odense University Hospital, Odense, Denmark; 20Department of Obstetrics & Gynecology, Gentofte Hospital, Gentofte, Denmark; 21Department of Neonatology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

OC06.01: Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial

K. Klein1, L. Rode2,3, K. Nicolaides4, E. Krampl-Bettelheim1, H. Larsen5, A. Holmskov6, K. Riis Andreasen7, N. Uldbjerg8, J. Ramb9, B. Bodker10, L. Skibsted11, L. Sperling12, S. Hinterberger13, L. Krebs14, H. Zingenberg15, E. Weiss16, I. Strobl17, L. Laursen18, J. Tranberg Christensen19, I. Vogel20, B. M. Hansen21, A. Lando21, A. Tabor2,3 1Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria; 2Department of Fetal Medicine 4002, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; 3Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark; 4Harris Birthright Research Centre for Fetal Medicine, King’s College Hospital, London, United Kingdom; 5Department of Obstetrics and Gynecology, Aalborg Hospital, Aalborg, Denmark; 6Department of Obstetrics and Gynecology, Viborg Hospital, Viborg, Denmark; 7Department of Obstetrics and Gynecology, Hvidovre Hospital, Hvidovre, Denmark; 8Department of Obstetrics and Gynecology, Aarhus University Hospital Skejby, Aarhus, Denmark; 9Department of Obstetrics and Gynecology, Sonderborg Hospital, Sonderborg, Denmark; 10Department of Obstetrics and Gynecology, Hillerod Hospital, Hillerod, Denmark; 11Department of Obstetrics and Gynecology, Roskilde University Hospital, Roskilde, Denmark; 12Department of Obstetrics and Gynecology, Herlev Hospital, Herlev, Denmark; 13Department of Obstetrics and Gynecology, General Hospital of Klagenfurt, Klagenfurt, Austria; 14Department of Obstetrics and Gynecology, Holbaek Hospital, Holbaek, Denmark; 15Department of Obstetrics and Gynecology, Glostrup Hospital, Glostrup, Denmark; 16Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria; 17Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria; 18Department of Obstetrics and Gynecology, Odense University Hospital, Odense, Denmark; 19Department of Obstetrics and Gynecology, Gentofte Hospital, Gentofte, Denmark; 20Department of Clinical Genetics, Aarhus University Hospital Skejby, Aarhus, Denmark; 21Department of Neonatology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

OC02.03: Increased nuchal translucency, normal karyotype and infant development

C. B. Miltoft1, C. K. Ekelund1, B. M. Hansen2, A. Lando2, O. B. Petersen3, P. Skovbo4, F. S. Jorgensen5, L. Sperling6, H. Zingenberg7, A. Nikkila8, A. C. Shalmi9, I. Stornes10, V. Ersbak11, A. Tabor1 1Fetal Medicine and Ultrasound, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; 2Department of Neonatology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; 3Department of Obstetrics and Gynaecology, Aarhus University Hospital, Skejby, Aarhus, Denmark; 4Department of Obstetric and Gynaecology, Aalborg University Hospital, Aalborg, Denmark; 5Fetal Medicine Unit, Department of Obstetrics and Gynaecology, Copenhagen University Hospital, Hvidovre, Copenhagen, Denmark; 6Department of Obstetrics and Gynecology, Copenhagen University Hospital, Herlev, Copenhagen, Denmark; 7Department of Obstetrics and Gynecology, Copenhagen University Hospital, Glostrup, Copenhagen, Denmark; 8Department of Obstetrics and Gynecology, Copenhagen University Hospital, Gentofte, Copenhagen, Denmark; 9Department of Obstetrics and Gynecology, Copenhagen University Hospital, Hillerod, Copenhagen, Denmark; 10Department of Obstetrics and Gynecology, Randers Hospital, Randers, Denmark; 11Department of Obstetrics and Gynecology, Silkeborg Hospital, Silkeborg, Denmark

Long-term effects of prenatal progesterone exposure: neurophysiological development and hospital admissions in twins up to 8 years of age: Prenatal progesterone exposure and outcome in twins

To perform a neurophysiological follow‐up at 48 or 60 months of age in children exposed prenatally to progesterone compared with a placebo and evaluate their medical histories up to 8 years of age.

P11.01: Development and establishment of a national Danish fetal medicine database for quality surveillance and research

were rated to enable highly diagnostic confidence (82.9%), and produce better image quality for the near field image (94.3%), the far field image (88.6%), and overall (94.3%). Conclusions: The current study described an objective method of comparing image quality acquired using different sonographic technologies. Ultrasound transducer incorporated with PureWave Crystal technology produces significantly better image quality for diagnostic purpose.